Emtricitabine/tenofovir alafenamide as Descovy® was recently granted a licence extension by the MHRA so that it can be used as PrEP in the four UK countries without this use being ‘off label’. Descovy® for PrEP is already approved by the American FDA.
As tradenames for preparations containing this combination vary according to indication, we have now two entries for emtricitabine/tenofovir alafenamide on the website:
- Emtricitabine/tenofovir alafenamide (trade names: Descovy, Taficita, Kocitaf (with dolutegravir))
- Emtricitabine/tenofovir alafenamide for PrEP (trade names: Descovy, PrEP)